Skip to main content
ANVS
NYSE Life Sciences

Annovis Completes Enrollment in Pivotal Alzheimer's Trial, Data Readouts Set for 2027

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.98
Mkt Cap
$82.957M
52W Low
$1.541
52W High
$5.5
52W Position info
29% above low
Off High info
64% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ANVS sits 29% above its 52-week low of $1.541.

Summary

Annovis Bio has fully enrolled its Phase 3 trial of buntanetap in early Alzheimer's disease, reaching the target of 850 patients across 83 U.S. sites. This is a critical milestone for the company, which has been navigating a precarious cash position and recent dilutive financings. The trial's dual readout design—6-month symptomatic data in Q1 2027 and 18-month disease-modifying data in Q1 2028—provides two near-term catalysts that could significantly de-risk the asset. With separate NDA submissions planned after each readout, the company is positioning for a potential accelerated path to market. The enrollment completion follows the $15 million offering in May that extended the cash runway, but the company will likely need additional capital before the first data readout.

At the time of this announcement, ANVS was trading at $1.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $83M. The 52-week trading range was $1.54 to $5.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.920 info
Change: +$0.0401 (+5%) info
Market Cap: $36.06M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.920 info
Change: +$0.0511 (+6%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 5:01 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.940
Real-time Price: $0.920 info
Change: -$0.020 (-2%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 4:07 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.8507
Real-time Price: $0.920 info
Change: +$0.0693 (+8%) info
Market Cap: $36.06M info
ANVS
Nov 04, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.880
Real-time Price: $0.920 info
Change: +$0.040 (+5%) info
Market Cap: $36.06M info